bafetinib

bafetinib

A Bcr-Abl/Lyn dual tyrosine kinase inhibitor, which may suppress the growth of CLL cells by inhibition of Lyn kinase. Imatinib-resistant CLL cells are associated with an overexpression of Lyn kinase, a factor in the proliferation and survival of B-CLL cells. It has no effect on c-Src kinase activity, and may be less toxic than other broad Src family kinase inhibitors. Bafetinib has shown therapeutic potential in phase-II trials in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.
References in periodicals archive ?
They show that giving the leukemia drugs nilotinib or bafetinib to fly larvae with the equivalent of Fragile X prevented the wild overgrowth of neuron endings associated with the disorder.
The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib.
That includes two trials for bafetinib, a possible treatment for people with certain advanced forms of leukemia.